A Phase 3 interventional study of KarXT and KarX-EC in Alzheimer Disease and Agitation, sponsored by Bristol-Myers Squibb. Recruiting at 255 sites in 26 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.
Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2025, is one of 10 in phase 3, and was the 5th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 2 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 14 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in United States, Argentina, Chile and 11 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 16 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 12 more countries
Ages 55–90
By country, each count listing its studies:
xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 463 across the 10 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
26 studies in Alzheimer Disease by Bristol-Myers Squibb: 12 open now, 13 under way, 10 of them phase 3. Of 13 finished, 0 (0%) have results posted.
Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 12 of the 12 other live ones, and was the 20th registered.
Bristol-Myers Squibb’s Alzheimer Disease studies by the year they started, since 2007.
3 of the studies testing xanomeline in Alzheimer Disease that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing xanomeline in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 26 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: KarXT · Drug: KarX-EC
Drug pages: Xanomeline · Trospium
Specified dose on specified days
Also known as: Xanomeline and Trospium Chloride capsule, BMS-986510
Specified dose on specified days
Also known as: Xanomeline enteric capsules, BMS-986519
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to approximately Week 30
Number of Participants With Adverse Events (AEs)
Time frame: Up to approximately Week 30
Number of Participants With Serious AEs (SAEs)
Time frame: Up to approximately Week 30
Number of Participants With TEAEs Leading to Study Withdrawal
Time frame: Up to approximately Week 30
Number of Participants With TEAEs Leading to Death
Time frame: Up to approximately Week 30
Number of Participants with Adverse Events of Special Interest (AESI)
Time frame: Up to approximately Week 30
Change From Baseline in Barnes Akathisia Rating Scale (BARS)
Time frame: Up to approximately Week 26
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)
Time frame: Up to approximately Week 26
Change From Baseline in Body Weight
Time frame: Up to approximately Week 26
Change From Baseline in Body Mass Index (BMI)
Time frame: Up to approximately Week 26
Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Heart Rate (HR)
This includes measuring of HR, both supine and standing or seated and upon standing after 2 minutes.
Time frame: Up to approximately Week 30
Number of Participants With Clinically Significant Changes in Orthostatic Vital Sign: Blood Pressure (BP)
This includes measuring of systolic and diastolic BP, both supine and standing or seated and upon standing after 2 minutes.
Time frame: Up to approximately Week 30
Number of Participants With Clinically Significant Changes in Laboratory Evaluations
Time frame: Up to approximately Week 30
Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG)
Time frame: Up to approximately Week 26
Number of Participants With Suicidal Ideations as Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to approximately Week 30
Number of Participants With Cognitive Impairment as Assessed by Mini-mental State Examination (MMSE)
Time frame: Up to approximately Week 26
Number of Participants With Cognitive Impairment as Assessed by 13-item Variation of ADAS-Cog Scale (ADAS-Cog-13)
Time frame: Up to approximately Week 26
Change From Baseline in the Severity of Benign Prostatic Hyperplasia as Assessed by International Prostate Symptom Score (IPSS)
This analysis is done in male participants.
Time frame: Up to approximately Week 26
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 255 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.
Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 42 months is close to that.
Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Xanomeline · Trospium